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A B S T R A C T
This small-scale macroscopic and quantitative authentication study, the ﬁrst of its kind in the UK and
elsewhere, assesses the identity and purity (excluding pesticides and heavy metals) of a selection of
Chinese materia medica (CMM) seeds and fruits on the UK market. 25 fruit and seed CMM were chosen
based on their inclusion in the Chinese Pharmacopoeia (2010, referred hereafter as ‘ofﬁcial species’),
maximum dimension of 10 mm, and regular use in Traditional Chinese Medicine (TCM) practice in the UK
according to UK practitioners. In 2012 samples were obtained from six TCM wholesale traders and eight
retail dispensaries in southeast England. Macroscopic identity and purity testing was undertaken
drawing on expertise at the Royal Botanic Gardens, Kew and its collection of vouchered CMM reference
drugs, herbarium specimens and published identiﬁcation texts. Of the 25 CMM requested from suppliers,
23 were obtained, represented by 211 samples. 191 samples were identiﬁed as being sourced from the
correct drug; 20 were identiﬁed as sourced from unofﬁcial species. Of the 191 correct samples, 5
displayed major contamination by other plant material, stones, earth, etc. (deﬁned as >5% of sample
volume), and 12 had minor contamination (2–5%). 95% of samples derived from medicinally cultivated
plants were sourced from an ofﬁcial species, 5% were contaminated; in contrast, 78% of wild-sourced
CMM samples were sourced from an ofﬁcial species, and 14% showed contamination. These results aim to
guide the further development of good practice in TCM herbal drug quality control, for which suggestions
are provided.
© 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Journal of Herbal Medicine
journal homepage: www.elsev ier .com/locate /hermed1. Introduction
The rise in global trade and use of Chinese materia medica
(CMM) as part of Traditional Chinese Medicine (TCM) practice has
become increasingly evident in the West during the last 30 years
(Liu et al., 2009); in the UK alone 400–500 CMM raw herbs are now
regularly traded and dispensed through many TCM suppliers and
clinics – at least 60 in London alone (Teng et al., 2008). The lack of
regulation governing the quality of these herbs has meant thatAbbreviations: ATCM, Association of Traditional Chinese Medicine and
Acupuncture UK; CMM, Chinese materia medica; CMIR, Chinese Medical Institute
and Register; CP, Chinese Pharmacopoeia; EBC, Economic Botany Collection, Kew
Gardens; EHTPA, European Herbal and Traditional Medicine Practitioners Associa-
tion; GA(C)P, (Good Agricultural (and Collection) Practices; MPNS, Medicinal Plant
Names Services; QA, Quality Assessment; RCHM, Register of Chinese Herbal
Medicine; TCM, Traditional Chinese Medicine.
* Corresponding author. Present address: School of Anthropology and Conserva-
tion, Marlowe Building, University of Kent, Canterbury, Kent, CT2 7NR, UK.
E-mail addresses: jmav3@kent.ac.uk (J.M.A. van der Valk), c.leon@kew.org
(C.J. Leon), m.nesbitt@kew.org (M. Nesbitt).
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2210-8033/© 2017 The Authors. Published by Elsevier GmbH. This is an open access artic
4.0/).many escape routine quality assessment (QA) checks, raising
concerns about the efﬁcacy of some TCM practices as well as public
safety (Teng et al., 2015).
Shortly following this increase in popularity, two Chinese
medicinal herbs were proven to be the cause of over 100 high-
proﬁle cases in western Europe of serious adverse reactions, some
fatal. These were due primarily to renal failure (McRae et al., 2002;
Perharic et al., 1995), and linked to what has been termed
“aristolochic acid nephritis” (Vanherweghem et al., 1993). These
events raised awareness of the importance of correct botanical
identiﬁcation, nomenclature and labelling of CMM, both for
assessing safety and, for scientiﬁc research into their efﬁcacy
and mechanisms of action (Atherton et al., 1993; Chan et al., 2012;
Farah et al., 2006). Many identiﬁcation manuals, studies of
individual CMM ingredients as well as pharmacopoeia QA
monographs have been published. However, many of these are
not readily accessible to traders and dispensaries, others require
technical expertise (often laboratory-based) to interpret and
others may be misleading if lookalike substitutes and contami-
nants are not included for comparison. Furthermore, systematicle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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dispensed are rare, and it is therefore hard to judge the extent of
the problem. In one of the few market surveys published, in Hong
Kong, Zhao et al. (2006b) identiﬁed 86 pairs of commonly confused
species found in TCM retail outlets.
For this study, a market survey and authentication exercise was
carried out in 2012, based in part on systematic purchasing of
selected CMM from retail dispensaries in London and Canterbury,
and in part on voluntary provision of samples by UK-based
wholesale suppliers. Small seeds and fruits (maximum dimension
10 mm) were chosen for the study because these were considered
to be among those CMM whose identity and purity are most
challenging to assess by traders and retailers, given their small size
and vulnerability to accidental or intentional contamination;
furthermore seeds were chosen because of the ﬁrst author’s
research training in seed identiﬁcation.
A wide range number of methods can be used for CMM
authentication, notably macroscopic and microscopic observation,
(physico)chemical or genetic analyses (Zhao et al., 2007), and most
recently, those based on advances in systems biology and “omic
techniques” (Buriani et al., 2012). For this study we relied solely on
macroscopic and to some extent organoleptic authentication,
using a hand lens and stereomicroscope, to examine gross
characteristics of seeds and fruits. The characteristics used include:
shape, size, colour, surface ornamentation, texture, fracture, cross-
section, smell and taste. These features arguably provide the
cheapest and fastest means to check CMM quality (Zhao et al.,
2011; Leon and Lin 2017).
2. Materials and methods
2.1. Sampling
A list of 25 CMM sourced from small seeds and fruits was
generated according to four criteria: 1) CMM ofﬁcially recognised
either as seed or fruit in the 2005 and/or 2010 editions of the
Chinese Pharmacopoeia; 2) seeds and fruits with maximum
dimension <10 mm (excludes nearly unmistakable seeds such as
Ginkgo biloba (Bai Guo) and Litchi chinensis (Li Zhi He); 3) presence
of macroscopic characters enabling robust identiﬁcation (some-
times to species level) and 4) CMM widely available in the UK. To
determine the last criterion we consulted with seven experienced,
UK-based TCM practitioners (>10 years of practice), asking them to
categorise by frequency of use a list of 50 herbs as “common”,
“average”, “rare”, or “don’t know”, and we also referred to the
EHTPA (European Herbal and Traditional Medicine Practitioners
Association) Core Curriculum listing the most clinically important
Chinese herbs (EHTPA, 2014).
A combination of sampling strategies was used to source the
samples. Suppliers were contacted via three TCM practitioner
associations in the UK: the Register of Chinese Herbal Medicine
(RCHM), Association for Traditional Chinese Medicine and
Acupuncture UK (ATCM) and the Chinese Medical Institute and
Register (CMIR). Herbal trade suppliers were sent a written
invitation, a short questionnaire and the list of study herbs using
Chinese, English, pharmacopoeia names. Two suppliers were the
source of only 1–2 samples; these were excluded from the analysis,
leaving 99 samples from 6 suppliers for inclusion in the analysis
(see Supplementary ﬁle 1). Clinics with Chinese herbal dispensa-
ries not afﬁliated to any practitioner association were found using
Google. A subset of these, in London and Canterbury, were visited
based on location and variation in clinic characteristics (size,
afﬁliation, part of TCM clinic chain). The list of selected seed and
fruit drugs (as in Supplementary ﬁle 1) was shown to the
dispensing staff, but excluding scientiﬁc names, and a small
sample (20–30 g) of each available CMM was bought. Twodispensaries could only supply 1–2 samples, so were excluded
from the analysis, which is based on 112 samples collected from 8
dispensaries.
Two of the CMM sought were not available from any of the
sources and were therefore excluded from further analysis: Qing
Ma Zi (Abutili Semen, seed of Abutilon theophrasti Medik.) and Tian
Xian Zi (Hyoscyami Semen, seed of Hyoscyamus niger L.). H. niger is
a restricted herbal ingredient only to be sold in the UK under
supervision of a registered pharmacist (MHRA, 2014), so its
absence was not surprising.
2.2. Authentication
Macroscopic authentication was carried out using the naked
eye, a hand lens (10 magniﬁcation) or a stereomicroscope with
light source (Olympus SZ 40, magniﬁcation 10–60) as diagnostic
tools. To complement the identiﬁcation expertise of the authors
each sample was also compared with Kew’s vouchered TCM
materia medica reference collection and wider herbarium collec-
tions, TCM identiﬁcation guides (Applequist 2006; Cappers et al.,
2006, 2009; Chen et al., 2010; Forestry Administration 2000; Guan
2000; Guo 1998, 2011; Leon and Lin 2017; Medicinal Biological
Products Department of Inspection, 2011; USDA, 2012), three key
Chinese trade authentication studies (Ho et al., 2006; Zhang, 2002;
Zhao et al., 2007) and a core reference text on the practice of
Chinese herbal medicine in Western countries (Bensky et al.,
2004). Detailed identiﬁcation criteria are given for some difﬁcult
cases in the discussion below.
When the appearance of sample seeds and fruits matched
descriptions and reference material of an ofﬁcial species for the
drug in question, the identiﬁcation was considered ‘correct’.
Identiﬁcation of unknown species, in the case of incorrect material,
is more difﬁcult. In some cases it may be possible to species level;
in others only to genus or above. These cases are discussed on a
drug-by-drug basis in Section 4.2.
Latin scientiﬁc names for the medicinal species discussed
follow the Kew Medicinal Plant Names Services database (MPNS,
2014); names of other species follow the Flora of China (Wu et al.,
1994). Author names for ofﬁcial CMM species are given in
Supplementary ﬁle 1; for other species at ﬁrst mention in the text.
The purity of each herb sample was assessed, with contamina-
tion described as ‘acceptable’ (<2%), ‘minor’ (2–5%) or ‘major’
(>5%). The threshold of 2% is based on that set in the 2015 British
Pharmacopoeia (British Pharmacopoeia Commission, 2014),
CP2010 and WHO (2011). Each sample was spread out in a thin
layer on a Petri dish and the level of contamination estimated by
sight. Our assessment of contamination excludes that due to
pesticides, heavy metals and micro-organisms and only includes
material visible under a 10 hand lens, comprising other plant
matter, soil or stones.
After authentication each sample was retained for reference as
part of the Economic Botany Collection (EBC) at the Royal Botanic
Gardens, Kew.
2.3. Deﬁnitions
We use the term ‘correct drug’ in this paper to refer to the
correct botanical source of a drug as speciﬁed in the Chinese
Pharmacopoeia (Chinese Pharmacopoeia Commission, 2010, here
referred to as CP2010). Where the CP2010 deﬁnes a single drug as
being sourced from more than one species or infra-speciﬁc taxa
these are all described as ‘correct drugs’ within the context of this
paper. We use the term ‘incorrect’ to refer to an entity which is not
one of these alternative CP2010 sources; note that such an
‘incorrect’ entity may be a different CP drug, a look-alike entity (but
not a CP drug) or a completely different entity that looks quite
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ofﬁcial CP drug. We emphasise such deﬁnitions here because they
may differ from those of many TCM texts and how such terms may
be used in clinical settings. For example, in a clinical setting it is
normal practice for a TCM practitioner sometimes to exchange (in
effect substitute) one ingredient (CMM) in a prescription for
another with similar or slightly different clinical properties
according to the pathology of the patient’s condition, the price
of the ingredient or the presence of certain other CMM in the
prescription etc. Therein lies one of the skills of an expert TCM
practitioner but such ‘clinical substitutions’ arise from intentional
prescribing and not from accidental use of an ‘incorrect entity’.
Essentially, because the focus of this paper is botanical identity and
not clinical substitution our deﬁnitions may differ from those used
in dispensary or clinical settings.
We use the term ‘adulterant’ when the occurrence of an
‘incorrect entity’ appears to have been intentional; such adulter-
ants are often look-alike substances or bulking agents (plant or
other) and may easily go undetected along a supply chain where
rigorous quality control is absent.
‘Cultivated’: refers to a drug cultivated as a medicinal crop
(regardless of scale) as opposed to one grown for ornamental or
other purposes, or harvested from the wild.
Of the 23 drugs studied here, ﬁve have multiple plant species
sources according to the CP2010; therefore all these species are
correct (in the context of their speciﬁc CP drug): Jue Ming Zi
(Cassiae Semen) can ofﬁcially be sourced from Senna obtusifolia or
S. tora; Che Qian Zi (Plantaginis Semen) from Plantago asiatica or P.
depressa; Chi Xiao Dou (Vignae Semen) from Vigna umbellata or V.
angularis; Man Jing Zi (Viticis Fructus) from Vitex trifolia subsp.
litoralis or subsp. trifolia; and Ting Li Zi (Descurainiae Semen/
Lepidii Semen) from Descurainia sophia or Lepidium apetalum.0 
Correct botanical  source Minor c ontamin ation (2 -5%) 
CP20 10 PinY in 
name CP20 10 Phar maco poe ia na me
Study herb 
list  numbe r
02sutcurFeaelarosPihZuGuB
E*6nemeSsinigatnalPiZnaiQehC
*9nemeSeangiVuoDoaiXihC
71sutcurFirunoeLiZieWgnohC
E61sutcurFeaihcoKiZuFiD
21sutcurFiisepraCihSeH
Hei Zhi  Ma Sesami Ni gru m Semen 7
Jiu Ca i Zi Alli i Tuberos i Semen  1
*3nemeSeaissaCiZgniMeuJ
*32sutcurFsicitiViZgniJnaM
E11sutcurFiitcrAiZgnaBuiN
Nü Zhen Z i Li gustri  Lucidi Fruc tus 18
Sha Yua n Zi Astrag ali  Compla nati  Se men 2
31sutcurFiidinCiZgnauhCehS
Suan Zao  Ren Ziziphi  Sp inos ae Se men 10
(Bei/Na n) Ting  Li Zi Le pidi i / Desc urai nia e Semen 5 *
8nemeSeairaccaVgniXuiLuBgnaW
(Bei) Wu Wei Zi Schisa ndra e Chinens is Fructu s 21
(Nan)  Wu Wei Zi Schisa ndra e Sphe nanth erae F ructu s 22
E41sutcurFeaidouEuYuhZuW
51sutcurFilucineoFgnaiXiuHoaiX
E4nemeSsicioCneRiYiY
E91sutcurFeallirePiZuSiZ
Fig. 1. A graphical overview of the main authentication r2.4. Nomenclature
The CP2010 uses various types of drug name for the title of each
drug entry: Latinised pharmacopoeia name, scientiﬁc name, Pin
Yin, Chinese and English names, e.g. Astragali Complanati Semen,
Phyllolobium chinense, Sha Yuan Zi, , ﬂatstem milkvetch seed.
However, for reasons of economy of space as well as botanical
clarity, the ﬁrst reference to a CP2010 drug name in this paper uses
the Pin Yin name followed by the pharmacopoeia name plus
currently accepted scientiﬁc name sourced from MPNS (2014), e.g.
Sha Yuan Zi (Astragali Complanati Semen, Phyllolobium chinense).
3. Results
The main authentication results are summarised in Fig. 1, and
are based on the data presented in Supplementary ﬁle 1.
Identiﬁcation and authentication comments for each sample are
provided in Supplementary ﬁle 2.
3.1. Overall patterns
Although authentication is the priority focus for this study (i.e.
determining if the correct drug has been supplied), the process of
authentication inevitably sheds light on other aspects of herbal
quality too: processing, freshness, purity (i.e. levels of contamina-
tion) and the identiﬁcation and safety of incorrect entities. Where
notable these herbal quality aspects are included in our ﬁndings
below.
Of the 23 drugs investigated, 13 (57%) had at least one sample
substituted by an unofﬁcial plant species (i.e. an incorrect entity) or
that was contaminated with organic or inorganic material above an
acceptable level. Overall, of the 211 samples investigated,191 (91%)
were sourced from the correct CP2010 plant species.1 2 3 4 5 6 7 8 9 10 11 12 13
Number of  studied  UK  market  samples (from  traders  and  dispensaries )
Major c ontamin ation (>  5%) Incorrect  species
esults. The asterisk (*) indicates EHTPA-listed herbs.
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identiﬁed as closely related species or genera: 5 samples named by
the trade as Sha Yuan Zi (seed of Phyllolobium chinense) were
substituted with Astragalus spp.; 7 named as Suan Zao Ren (seed of
Ziziphus jujuba var. spinosa) were substituted with that of Z.
mauritiana, and 2 named as Bei Wu Wei Zi (fruit of Schisandra
chinensis) were substituted with that of S. sphenanthera. For 6Fig. 2. Photographic grid of noteworthy trade issues. The small scale bars are 1 mm, the l
seed of Phyllolobium chinense, EBC 83804 (dispenser 1) heavily contaminated with unide
83804 showing range of seed contaminants. C. Kew reference drug (top left) of Sha Yuan
reference seeds from the Kew Legume Seed Collection of closely related genera: Astragalu
right), Crotalaria pallida Aiton (bottom left), and Abutilon indicum (L.) Sweet (bottom right
ofﬁcial source species: Plantago asiatica (right, EBC 82352) and P. depressa (left, EBC 832
Ziziphus jujuba var. spinosa, EBC 81794). Right: sample traded as ‘Suan Zao Ren’ but identi
reference drug of He Shi (Carpesii Fructus, nutlet of Carpesium arbotanoides, C-Standard-
right: sample traded as ‘He Shi’ nutlet but identiﬁed as nutlet of Torilis japonica (sold by su
frutescens, EBC 83983, dispenser 8) but heavily contaminated by nutlet of other species, p
left) and Kew reference nutlet of three species of Mosla (M. dianthera, bottom left; M. scab
frutescens in the top photo, compared to those of the Kew reference drug, are probably a w
Gu Zhi (Psoraleae Fructus, nutlet of Cullen corylifolium, EBC 82989). Right: sample traded
(EBC 83939, supplier 5). J. Left: Kew reference drug of Man Jing Zi (Viticis Fructus, nutlet
83939, supplier 5) but identiﬁed as V. negundo nutlet, an unofﬁcial substitute.samples, entirely unrelated species were supplied: 1 sample of Che
Qian Zi (seed of Plantago asiatica, P. depressa) was substituted by
Bupleurum sp.; 2 of He Shi (fruit of Carpesium abrotanoides)
substituted by Torilis japonica; 2 of Man Jing Zi (fruit of Vitex trifolia
subsp. litoralis and subsp. trifolia), one substituted by fruit of
Ligustrum lucidum and the other by that of Vitex negundo; and one
of Bu Gu Zhi (Cullen corylifolium) substituted by an unidentiﬁedarge scale bars 1 cm. A. Sample traded as ‘Sha Yuan Zi’ (Astragali Complanati Semen,
ntiﬁed seed of closely related genera (possibly Astragalus and Crotalaria). B. detail of
 Zi (Astragali Complanati Semen, seed of Phyllolobium chinense, EBC 82195) and ﬁve
s sinicus L. (top right), A. sinensis Turrill (centre left), Aeschynomene indica L. (centre
). D. Kew reference drug of Che Qian Zi (Plantaginis Semen) showing seed of the two
40). E. Left: Kew reference drug of Suan Zao Ren (Ziziphi Spinosae Semen, seed of
ﬁed as seed of the unofﬁcial substitute Z. mauritiana (EBC 83929, supplier 5). F. Top:
3966). Lower left: reference nutlet of Daucus carota ‘Nan He Shi’, EBC 83081). Lower
pplier 5, EBC 83828). G. Sample traded as ‘Zi Su Zi’ (Perillae Fructus, nutlet of Perilla
ossibly Mosla. H. Kew reference drug Zi Su Zi (nutlet of P. frutescens, EBC 81840, top
ra, bottom right; M. chinensis, top right). N.B. the slightly larger and paler nutlets of P.
ell-known cultivar of P. frutescens called ‘Bai Su Zi’. I. Left: Kew reference drug of Bu
 as ‘Bu Gu Zhi’ but heavily contaminated with black seed of an unidentiﬁed species
 of Vitex trifolia subsp. trifolia EBC 80016). Right: sample traded as ‘Man Jing Zi’ (EBC
44 J.M.A. van der Valk et al. / Journal of Herbal Medicine 8 (2017) 40–51seed. In this last case the same supplier also provided a correctly
sourced sample of Bu Gu Zhi, the only case where the same drug
was supplied twice from one supplier.
Contamination is only quantiﬁed in Supplementary ﬁle 1 for
samples identiﬁed as the correct CP2010 drug. Of these samples, 5
showed major contamination and 12 showed minor contamina-
tion. Hence 17 samples displayed unacceptable levels of contami-
nation. Overall, 174 samples (82%) were of good quality, deﬁned
here as being both sourced from the correct drugs and with low
levels of contamination.
Other quality concerns not included in Supplementary ﬁle 1
include non-standard processing, mixing of 2 ofﬁcial species
within one sample (e.g. two ofﬁcial Senna species for Jue Ming Zi),
atypical odour (one rancid Chong Wei Zi sample, one Niu Bang Zi
sample smelling like fennel) and suspected counterfeiting by
means of a dye (in three Wu Wei Zi samples). Insect remains
(particularly of beetles, Coleoptera) were found in 4 samples.
The availability of the 23 drugs from all 14 suppliers varied
considerably. No single supplier was able to provide samples of all
the drugs requested. 14 suppliers were able to provide somewhere
between 11 and 13 drugs, and a further 7 to 10 suppliers were able
to provide at least 6 drugs.
3.2. Drug sample analysis
Two drugs were supplied by a high proportion (>50%) of
suppliers and demonstrated high levels of substitution (>50% of
samples): Sha Yuan Zi (Astragali Complanati Semen, Phyllolobium
chinense) and Suan Zao Ren (Ziziphi Spinosae Semen, Ziziphus
jujuba var. spinosa). Three drugs exhibited high levels of substitu-
tion (33–100% of samples) but relatively few samples were
supplied, meaning that these ﬁgures must be treated as less
robust indicators of a widespread problem: Man Jing Zi (Viticis
Fructus, Vitex trifolia subsp. litoralis), Bei/Wu Wei Zi (Schisandrae
Chinensis Fructus, Schisandra chinensis) and He Shi (Carpesii
Fructus, Carpesium abrotanoides).
One drug was widely available and had frequent occurrence of
minor or major contamination (42% of 12 samples): She Chuang Zi
(Cnidii Fructus, Cnidium monnieri). Other drugs showing 25% or
more of contaminated samples were Che Qian Zi (Plantaginis
Semen, Plantago spp.), Chong Wei Zi (Leonuri Fructus, Leonurus
japonicus) and Di Fu Zi (Kochiae Fructus, Bassia scoparia).
Several of the substitutes identiﬁed have previously been
reported in the TCM trade authentication literature (see below);
these are Astragalus spp. for Sha Yuan Zi (Astragali Semen),
Zizyphus mauritiana for Suan Zao Ren (Ziziphi Semen) and Torilis
japonica for He Shi (Carpesii Fructus). However, one case of
substitution is reported here for the ﬁrst time: Bupleurum sp. fruits
for Che Qian Zi (Plantaginis Semen).
3.3. Suppliers
There was a small but consistent difference in herbal quality
between the wholesalers and retail dispensaries. 92% of samples
from wholesalers (n = 99) were of the correct CP2010 drug, while
those from dispensaries (n = 112) were 89% correct; 5% of samples
from wholesalers had minor or major contamination; in contrast,
11% of samples from dispensaries were contaminated.
3.4. Wild versus cultivated source
The cultivation status of most TCM herbs is well documented;
nonetheless, absolute certainty is difﬁcult as a species may be wild
or cultivated or both according to its local provenance. The
designations in Supplementary ﬁle 1 should be regarded as
indicative, for the purpose of data analysis. Where taxa are knownto be both wild harvested and cultivated they were excluded from
the analysis: Niu Bang Zi (Arctii Fructus), Yi Yi Ren (Coicis Semen),
Nan Ting Li Zi (Descurainiae Semen) and Che Qian Zi (Plantaginis
Semen). Plants considered ‘mainly cultivated’ were treated as
‘cultivated’ for the analysis.
There was a major difference between wild and cultivated plant
sources. 95% of samples derived from cultivated plants (n = 103)
were identiﬁed as sourced from a correct species, and 5% showed
minor or major contamination. 78% of samples from wild plants
(n = 64) were identiﬁed as sourced from of a correct species, and
14% showed contamination.
4. Discussion
4.1. Limitations of the study
The results of this pilot study must be interpreted with caution.
The 23 drugs studied represent a small proportion of the 400–500
Chinese herbal drugs currently on the market in the UK, and the
wholesalers and dispensaries are again an incomplete sample: for
example, there are estimated to be 60+ TCM retail dispensaries in
London alone (Teng et al., 2008, 2015). In some cases only a few
samples of a TCM drug were supplied by our sources. Furthermore,
these results cannot be regarded as applicable to manufactured
herbal products, which are produced in a factory setting with the
potential for greater control of quality. Occurrence of heavy metals
and pesticides (both known to be a problem in Chinese herbal
drugs) or other micro-biological contamination, was not assessed.
4.2. Herb-by-herb authentication of selected trade samples
4.2.1. Sha Yuan Zi –Astragali Complanati Semen
Of the eight trade samples of Sha Yuan Zi examined, only three
were consistent with Kew’s seed reference specimens of Phyllo-
lobium chinense, the CP2010 source species for this drug (most TCM
literature including the CP2010 refers to it by its synonym
Astragalus complanatus R. Br. ex Bunge). The species is a perennial
herb with pinnate leaves and yellow to pinkish-red ﬂowers borne
in tightly clustered vertical heads and is endemic to W, C, E and NE
China. Its seeds are somewhat kidney-shaped and slightly
ﬂattened (2–2.5 mm  1.5–2 mm); the testa is brownish-green or
greenish-brown and slightly paler around the small, round hilum
which is situated at the centre of a distinct ventral indentation.
The seeds in the remaining ﬁve samples bear some resemblance
to P. chinense but are a better match with seed of other species in
the genus Astragalus; the latter is a taxonomically challenging
genus closely related to Phyllolobium, comprising 400 species in
China and requires specialist botanical knowledge for identiﬁca-
tion to species level (even when whole plants are available). In
contrast to P. chinense seed these seeds (as observed by the ﬁrst
author) have a dull greenish-brown testa, often mottled with dark
brown spots, and a faint reticulate pattern of small surface cells
(Fig. 2A, B). Given that Phyllolobium chinense is wild-harvested in
many Chinese provinces and its source plants as well as seed are
easily confused with those of species in the ubiquitous genus
Astragalus (Fig. 2C), identiﬁcation confusion at source is likely to
account for the high levels of seed contamination.
Inorganic contamination, mainly in the form of small stones,
along with smaller soil particles, was found in six samples. These
stones are of a similar size, shape and colour to the seeds of Sha
Yuan Zi, suggesting probable intentional bulking up.
4.2.2. Che Qian Zi – Plantaginis Semen
Che Qian Zi is ofﬁcially sourced (CP2010) from seed of either
Plantago asiatica or P. depressa. (see Fig. 2D). Both species are short,
perennial herbs with leaves in a basal rosette and tiny ﬂowers
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Che Qian Zi in trade is reported to be sourced from P. asiatica, which
is widely cultivated on medicinal plant farms; P. depressa is entirely
wild harvested. There is no commercial need to distinguish the
seed of the two ofﬁcial species since they are considered to have
very similar clinical actions, however macroscopic differentiation
is possible under an 10 hand lens: P. depressa seed is smaller (0.9–
1.7 mm long; 0.6–0.9 mm diam.) than that of P. asiatica (1.2–2 mm
long; 1 mm wide) and is less angular. But identiﬁcation of P.
depressa seed in this study is indicative only because, being wild
harvested, seed cannot be differentiated from the other 20 wild
Chinese species of Plantago using macroscopic characters alone.
Of the 12 trade samples studied here, 11 were consistent with
Kew’s authentic reference seed of P. asiatica. Two samples
appeared to have been processed with salt; this a traditional
processing method described in CP2010. The main contaminant
common to all three samples closely resembled fruits of Bassia
(synonym Kochia) in the Amaranthaceae family of which B.
scoparia is the most widespread by far, growing wild throughout
China. Its fruits are the source of a separate CP2010 drug ‘Di Fu Zi’
(Kochiae Fructus). One sample was almost completely substituted
by fruit material resembling the fruit mericarps of a member of the
Apiaceae family, possibly in the genus Bupleurum.
4.2.3. Suan Zao Ren – Ziziphi Spinosae Semen
Suan Zao Ren is ofﬁcially sourced from the seed of wild Ziziphus
jujuba var. spinosa and is a widespread, spiny and deciduous shrub
(up to 10 m) endemic to northern China and producing, in late
summer, red-purplish fruit with a distinctively spongy, sour-
tasting ﬂesh. It is widely used for hedging in China owing to its
sharp spines. A different variety, Z. jujuba Mill. var. jujuba, is widely
cultivated for its sweet, spongy fruit and is the source of a separate
TCM drug called Da Zao (Jujubae Fructus).
Of the 12 trade samples examined, 5 were consistent with
Kew’s authentic reference seed of Suan Zao Ren (i.e. the ofﬁcial
CP2010 species) of which two had undergone dry-frying, a
traditional TCM processing method which typically slightly
inﬂates and darkens the seed. Contamination levels by other plant
materials (in this case in endocarp fragments) in these 5 correctly
sourced samples were considered to be within acceptable limits
(i.e. <2%).
Seven samples were substituted in their entirety by seeds
resembling those of Z. mauritiana Lam. The latter species is widely
cultivated in China for its edible fruit (Hu, 2005) and it is plausible
that its seed (normally discarded) has been used here as a cheap
look-alike substitute for the ofﬁcial drug. Whole plants of the two
species are easily distinguished as are their seeds (Fig. 2E).
Although superﬁcially similar, Z. mauritiana seeds are more
rounded and thinner (6–7 mm long; 5–6 mm wide; 2 mm thick),
while seed of the ofﬁcial species is ellipsoidal or oblate (5–9 mm
long; 5–7 mm diam.; ca. 3 mm thick); the testa of Z. mauritiana is
usually lustrous and yellowish- or reddish-brown (as opposed to
slightly lustrous and reddish- or purplish-brown in the ofﬁcialTable 1
Identiﬁcation criteria for fruits of Carpesium abrotanoides, Torilis japonica, and Daucus c
Character Carpesium abrotanoides Torilis japonica 
size (without
spines)
3.5–4 mm long;
0.5 mm diam.
2.0–3.8 mm long;
1.2–1.5 mm diam.
shape narrowly cylindrical ovoid-ellipsoid 
dorsal surface several shallow longitudinal ribs; bristles absent 3 broad dorsal ribs,
long) with spines c
stylopodium spreading like a beak (0.7 mm long) to form an
apical cartilaginous ring
conical, not spreadspecies) and the ventral surface is smooth while the ofﬁcial species
usually has a longitudinal ridge or furrow, or is randomly ﬁssured
(Leon and Lin 2017: 722–723).
4.2.4. He Shi – Carpesii Fructus
He Shi is ofﬁcially sourced from the fruit of Carpesium
abrotanoides, a much branched, perennial herb in the Asteraceae
family. The species has simple, alternate, elliptic leaves with small
branching clusters of ﬂowerheads (capitula) arising from the leaf
axils; each capitulum contains 130–300 tiny, yellow, densely
packed ﬂorets which develop into cylindrical and longitudinally
ribbed achenes (ca. 3.5 mm long  1 mm diam.), the source of He
Shi. The plant is widely distributed as a ruderal throughout China
except in the North.
Although only two samples were supplied, neither were the
correct drug. Instead, they were identiﬁed as the spiny and much
larger fruits of Torilis japonica (Houtt.) DC. (Apiaceae family) a
widespread species in China, whose fruits are used in local
medicine. Their occurrence as an adulterant of He Shi is widely
reported (Bensky et al., 2004; Zhao and Xiao 2010) and it is likely
this is due to confusion about their similar Chinese names
(Hua Nan He Shi and He Shi) rather than mistaken identity; Torilis
fruits are easily distinguishable from those of He Shi (Fig. 2F; for
identiﬁcation criteria, see Table 1).
4.2.5. She Chuang Zi – Cnidii Fructus
She Chuang Zi is ofﬁcially sourced from the fruit of Cnidium
monnieri (family Apiaceae). The species is an annual herb with 1–3
pinnate leaves and tiny, white, 5-petalled ﬂowers borne in
compound, 15–20-ﬂowered umbels (ca 2–4 cm diam.). Fruits are
dry, brittle and ovoid-ellipsoid (1.5–3 mm long; 1–2 mm diam.)
with a persistent swollen style base (stylopodium) at the apex and
occasionally with 2 recurved styles. At maturity fruits split into 2
mericarps; each mericarp has a ﬂat ventral surface with 2 brown
longitudinal oil ducts (vittae) and a dorsal surface with 5
distinctive cork-like wings. The trade item, She Chuang Zi, mostly
consists of these separated mericarps and which, when crushed,
are distinctly aromatic.
All 12 samples were consistent with Kew’s reference material of
C. monnieri (Leon and Lin 2017: 717). Four samples showed minor
contamination and one showed major contamination; the
contaminant in all these samples resembled fruits in the
Amaranthaceae family, probably the genus Bassia (synonym
Kochia; see also Che Qian Zi above).
4.2.6. Zi Su Zi – Perillae Fructus
Zi Su Zi is ofﬁcially sourced from the nutlets of Perilla frutescens
(Lamiaceae family). The species is an annual herb (0.3–2 m tall)
with ovate leaves varying in colour according to variety. Tiny white
to purplish-red ﬂowers are borne in short cylindrical heads and
develop into greyish-brown, almost spherical, 1-seeded nutlets
(1–1.5 mm diam.) with a distinctive and slightly raised reticulated
surface. The species has long been cultivated in east-central Chinaarota (latter reported elsewhere as a substitute of He Shi, Bensky et al., 2004).
Daucus carota
2.2–4.0 mm long;
1.2–1.9 mm diam.
ovoid-ellipsoid
 covered densely in spines (0.5-0.8 mm
urving towards apex
4 broad dorsal ribs, covered densely in
straight spines ca 1 mm long
ing conical, not spreading
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Geng), each recognised as a separate medicinal ‘herb’ in the
CP2010. The species is also widely cultivated in China for its leaves
and ﬂowerheads as a culinary ingredient, and the seed oil is used as
a waterprooﬁng agent (Yu, 1997). In addition to the three wild
varieties of this species (Wu et al., 1994), the diverse uses outlined
above have also led to the development of many cultivars which
exhibit considerable variation in leaf and fruit morphology. The
CP2010 does not mention any cultivar(s) by name as the speciﬁc
source of Zi Su Zi so it would appear that any can be used; its
description of the nutlets reads (translated from the Chinese)
‘about 1.5 mm diameter, externally greyish-brown, with dark purple
and slightly raised reticulate striations’.
In the eight samples obtained the nutlet morphology was
broadly consistent with the CP2010 description and Kew’s
reference material of Perilla frutescens (Leon and Lin 2017:
768–769). However, nutlets in ﬁve samples were markedly larger
than the size stated in the CP2010 (ca 1.5 mm diam.) with most
falling in the range 1.9–2.7 mm and another two samples were
markedly smaller (0.6–1.3 mm diam.). These are signiﬁcant size
differences. Considerable variation in colour (greyish-brown, pale
creamy-yellow, yellowish-brown and purplish-brown) and varia-
tion in the prominence of the reticulated nutlet surfaces was also
noticed between samples (Fig. 2G, H). It is possible that these
samples were harvested from cultivars which exhibit a more
variable nutlet morphology than those forms of P. frutescens that
are ofﬁcially recognised as acceptable sources of Zi Su Zi. It is also
possible that the nutlet having been dry-fried, a traditional
processing procedure that slightly darkens the nutlet surface and
which may even cause the nutlet to swell. However the samples in
this study did not have the appearance of having been dry-fried. To
bring clarity to these UK market ﬁndings, further research is
recommended into which cultivars of P. frutescens are considered
suitable for sourcing Zi Su Zi, and whether amendment to the
current CP2010 macroscopic description is required.
The variability in nutlet appearance makes detection of
contaminants in these samples difﬁcult. Two samples, at least,
were possibly contaminated by nutlets of another species, with
different reticulation leading to an almost sculpted surface, small
size (0.6–1.3 mm diam.) and the virtual absence of an areola at one
end. These may be nutlets of species in the genus Mosla (closely
related to Perilla) which have been reported as contaminants or
adulterants of Zi Su Zi on the Chinese market (NICPBP 1997–2002;
Bensky et al., 2004). It is not possible to discriminate between the
nutlets of all 13 Chinese Mosla species solely on the basis of
macroscopic characters, and for reliable detection, laboratory-
based authentication methods are advised.
4.2.7. Bu Gu Zhi – Psoraleae Fructus
The ofﬁcial source of Bu Gu Zhi is the fruit of Cullen corylifolium
(family Fabaceae). This is an annual herb (0.6–1.5 m tall) with
leaves, and especially calyx, dotted with black glands and ﬂowers
yellow or blue and borne in dense, axillary ﬂowerheads. The crude
drug is made from the fruits, which are dry, ovoid and often
reniform (ca. 5 mm long) with a blackish-brown or greyish-brown,
brittle and densely reticulated periderm; with an apical end with a
small prominence and the basal end slightly depressed with a tiny
fruit-stalk scar; each fruit contains one seed.
Examination of the 12 trade samples obtained, revealed that 11
were completely consistent with the fruit of Kew’s reference
material of the Cullen corylifolium (as described above). Two or
three samples showed some (albeit negligible) evidence of sub-
standard processing owing to the persistence of the distinctive
membranous, black gland-dotted calyx still attached at the base;
calices are normally removed when traditionally processed.
Another sample showed evidence of having been dry-fried withsalt (a traditional TCM processing method), recognised by the
slightly different appearance of the pericarp: pale brown and
slightly inﬂated or cracked. The one sample that did not comply
with the reference material was very heavily adulterated (ca 90%)
with an unpleasant-smelling sub-ovoid seed (3–4  2–3 mm) with
a thin, mat and brittle testa (not reticulated), frequently dented and
sometimes cracked to reveal two blackened cotyledons within
(Fig. 2I). Its identity has not been established; dry-fried radish seed
(Raphanus sativus L.) was considered as a possibility. This is the
source of a separate TCM herb ‘Lai Fu Zi’ (Raphani Semen),
but we have been unable to conﬁrm this. To the naked eye the
unknown seeds superﬁcially resemble fruits of Cullen corylifolium;
whole plants are very different in appearance, suggesting
intentional adulteration but for reasons unknown.
Care was taken when examining all these trade samples to
ensure the absence of seed of Datura spp. (Solanaceae), notably D.
stramonium L. and D. inoxia Mill.; these are toxic, bear a close
resemblance to Bu Gu Zi and both have been reported as
contaminants of Bu Gu Zi (Bensky et al., 2004; NICPBP
1997–2002 vol. 3). No such contamination was found in any of
the samples.
4.2.8. (Bei) Wu Wei Zi ( ) – Schisandrae Chinensis Fructus
(Nan) Wu Wei Zi ( ) – Schisandrae Sphenantherae Fructus
Bei Wu Wei Zi (also known as Wu Wei Zi) is ofﬁcially sourced
from the fruits of Schisandra chinensis and Nan Wu Wei Zi from S.
sphenanthera (family Schisandraceae). The two species are
discussed together here because although ofﬁcially recognised
as the source of two separate TCM drugs (from the CP2000
onwards), they are often used interchangeably in a clinical setting
due to their similar pharmacological actions, and because they are
difﬁcult to distinguish macroscopically. Clinical preference exists
for S. chinensis however and this is reﬂected in trade prices. Owing
to increasing demand, especially in overseas markets where it is
marketed as a health food, S. chinensis has recently been brought
into commercial cultivation in parts of north-east China, and Good
Agricultural Practice (GAP) certiﬁcation awarded at some produc-
tion sites in Jilin province (Zhang et al., 2010). S. sphenanthera
continues to be sourced only from wild populations.
The two species are deciduous climbers with S. chinensis found
wild in slightly more northerly parts of China compared to S.
sphenanthera, hence their preﬁxes ‘Bei’ [north] and ‘Nan’ [south].
Both have elliptical leaves, solitary 5–9 ‘petalled’ ﬂowers and
pinkish-red ovoid fruits developing in pendant clusters. The main
differences are to be found in their ﬂower colour (white or whitish-
yellow in S. chinensis; yellow, orange or red in S. sphenanthera) and
in the number of their stamens.
The macroscopic identiﬁcation of Wu Wei Zi to species level can
be challenging, especially when the fruits are dried. A pure, good
quality sample of Bei Wu Wei Zi is usually straightforward but a
lower quality and less homogeneous sample is often problematic
especially where mixed species samples are suspected. Accord-
ingly, samples in trade are easily confused, accidentally or
intentionally for the reasons outlined above. The main distinguish-
ing characters of Nan Wu Wei Zi are: fruits less ﬂeshy and often
smaller (c. 5–5.5 mm diam.); fruit wall dull, brownish-red to dark
brown with seed difﬁcult to remove cleanly; seed slightly smaller
and more rounded (3–3.5  3.5–4 mm; Bei Wu Wei Zi 3.2-
3.8  4.4–4.8 mm); seed coat dark greyish-brown, mat, somewhat
verrucose (warty) (Upton, 1999; Leon and Lin 2017: 687, 742–743;
authors’ personal observations).
13 samples were obtained, requested under each name: Bei Wu
Wei Zi and Nan Wu Wei Zi. 5 suppliers did not attempt to
distinguish the two species and simply supplied their samples as
Wu Wei Zi; these were identiﬁed as S. sphenanthera. The other 8
samples were supplied with the more precise preﬁxes Bei ( ,
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by the supplier as Bei Wu Wei Zi were identiﬁed as S. sphenanthera.
Whether such mis-naming was intentional or accidental is
unclear; possibly a mix of the two is most likely given the price
differential between the 2 species.
Three samples (2 supplied under the name ‘Wu Wei Zi’ and one
as ‘Nan Wu Wei Zi’) were found to be adulterated with a red dye.
This was detected when the fruits were immersed in water and a
strong pinkish-red colour was instantly released (Fig. 3). In the dry
material of these samples we had noted that contaminant pieces of
stem in each of these samples were unusually dark and vivid red
suggesting adulteration. Bei Wu Wei Zi are typically a strong red
colour compared to duller Nan Wu Wei Zi, so the use of a red dye in
the latter is plausible as an attempt to pass them off in trade as fruit
of the former more expensive herb. Our research indicates
confusion in the UK market in respect of which species are being
traded as Wu Wei Zi.
4.2.9. Man Jing Zi – Viticis Fructus
Man Jing Zi is sourced from the small, hard round fruits of
Vitex trifolia (Lamiaceae family), mostly from subspecies litoralis
(appears under the synonym V. trifolia var. simplicifolia Cham. in
CP2010). This subspecies is a prostrate shrub with small
purplish-mauve ﬂowers, widely cultivated near lakes and along
coastal areas in central and south-eastern China. Subspecies
trifolia is an alternative ofﬁcial source whose fruits are virtually
indistinguishable from those of the above (the scientiﬁc
nomenclature for this in the CP2010 is ambiguous but it is
assumed that this type subspecies is intended since the other
subspecies is named in full).
Of the ten UK trade samples acquired as Man Jing Zi, eight were
identiﬁed as consistent with Kew’s reference samples of V. trifolia
fruit (i.e. ofﬁcial Man Jing Zi); these could be further separated into
subsp. trifolia (6 samples) and subsp. litoralis (2 samples) (Leon and
Lin 2017: 680–681). One of the subsp. trifolia samples was typical
of the Hong Kong trade style of Man Jing Zi where fruit calyces are
removed and another was signiﬁcantly contaminated (15%) with V.
negundo fruits (see below). The two remaining samples were
totally incorrect. One was identiﬁed as fruit of V. negundo L. easily
identiﬁed as smaller (3–4  2–3 mm, as opposed to 4–5  4–6 mm)Fig. 3. Left: Kew reference drug of Nan Wu Wei Zi (fruit of Schisandra sphenanthera, EBC 
Nan Wu Wei Zi (S. sphenanthera) and dyed (middle petri dish). Right: Kew reference drug
immersion in water. The ruler indicates 1 mm.with a shallowly- (as opposed to deeply-) toothed persistent calyx
enclosing at least half (as opposed to one-third) of the fruit (Fig. 2J).
V. negundo fruits are a commonly reported substitute or adulterant
of Man Jing Zi. They are used in Chinese folk medicine (albeit for
different clinical conditions) and the leaves of the species are also
widely used for large-scale extraction to produce the separate TCM
herb ‘Mu Jing Ye’ (Viticis Negundo Folium); as such the fruits may
be readily available as a cheap look-alike for ofﬁcial Man Jing Zi. An
accidental cause of substitution may also arise due to potential
confusion of the similar Chinese trade names of these two herbs;
V. negundo fruit is often called Huang Jing Zi ( ) and when this
and Man Jing Zi ( ) are shortened in trade circles to Jing Zi
( ) confusion may ensue.
The other incorrect sample was considered a straightforward
dispensing error since although the supplier’s jar was labelled
‘Man Jing Zi’ its contents were easily identiﬁed as Ligustrum
lucidum fruit which is a separate and easily distinguished TCM herb
(Nu Zhen Zi ).
4.3. Possible causes of substitution, adulteration and contamination
Chinese herbal drugs present a special challenge in documen-
tation and authentication, in part simply because of the number of
species involved (500+) and the size of the country in which they
are produced and used (Zhao et al., 2006a,b; Leon and Lin 2017).
Many materia medica can be sourced from more than one ofﬁcial
species, or from unofﬁcial substitutes, both of which may reﬂect
supply shortages or price differentials. In addition, the choice of
plant part and processing technique are further variables (Zhao
et al., 2010). We have drawn on two approaches to clarify the
patterns observed here: Zhao et al.’s (2007) analysis of deliberate
and accidental forms of substitution in Chinese materia medica, as
modiﬁed in our Table 2, and Booker et al.’s (2012) study of value
chains in the supply of herbal medicines, which highlights the
many loci and individuals involved in the typical supply chain.
Although existing studies on value chains focus on their inﬂuence
on village-level livelihoods, there is obvious potential for study of
their effect on medicinal plant quality.
The marked difference in quality between drugs harvested from
the wild, of which 36% of samples were either of the incorrect80419). Middle: sample traded as ‘Wu Wei Zi’ (EBC 83897, dispenser 7), identiﬁed as
 of Bei Wu Wei Zi (fruit of S. chinensis, EBC 80572). Top row: the 3 samples after brief
Table 2
Possible reasons for identiﬁcation and purity issues of single, loose dried herbs (cf. Zhao et al., 2006a,b). The table does not incorporate chemical and microbiological
contamination as these often cannot be detected macroscopically.
1 Sourcing
1a multiple ofﬁcial sources (different versions of) the Chinese Pharmacopoeia, other (inter)national pharmacopoeias
1b regional source listed in provincial publications (e.g. Guangdong pharmacopoeia)
1c local source used locally as a substitute
2 Naming
2a botanical nomenclature lack of authority, synonyms, unresolved names
2b other names Chinese, Pinyin, Pharmacopoeia, and English names, etc.
3 Morphological similarity
3a whole plant entire plants look alike
3b plant part targeted plant parts of different plants look alike
3c counterfeiting artiﬁcially manufactured to look alike
4 Plant part wrong plant part(s)
5 Processing processing not mentioned, non-standard processing
6 Dispensing error wrong label on batch or sample
7 Contamination
7a ﬁeld contamination collected/harvested together with drug source
7b cross-contamination adhering to processing equipment, container, during transport
7c intentional added to artiﬁcially increase the amount of product
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cultivation, with the corresponding ﬁgure of 10%, points to the
origin of the drugs as a crucial factor. In the case of Sha Yuan Zi
(Astragali Complanati Semen), Phyllolobium chinense is substituted
by one or more species from a very closely related genus,
Astragalus, with plants and seeds that are very similar in
morphology, to the extent that P. chinense was until recently
classiﬁed as an Astragalus species. These seed contaminants are
most likely to be entering trade through accidental confusion
during wild harvesting. In contrast, the occurrence of the sample
substituted with an Apiaceae fruit (not known as a TCM drug) is
more likely to be due to intentional adulteration owing to its
superﬁcial resemblance. The other wild-harvested drug to show a
high incidence of substitution (probably intentional) is Suan Zao
Ren (Ziziphi Spinosae Semen) where the seeds of Ziziphus jujuba
var. spinosa have been substituted with those of the widely
cultivated Z. mauritiana.
Higher levels of contamination in wild-harvested species
doubtless reﬂect the inadvertent harvesting of nearby plants. Of
the contaminant species, Bassia (synonym Kochia) fruit is clearly
the most signiﬁcant, turning up in three samples of She Chuang Zi
(Cnidii Fructus), three samples of Che Qian Zi (Plantaginis Semen)
and one sample of Chong Wei Zi (Leonuri Fructus). Cnidium
monnieri fruit (i.e. She Chuang Zi) is a close second, and was found
in 4 samples of Chong Wei Zi (Leonuri Fructus) and 1 of Di Fu Zi
(Kochiae Fructus). Bassia, Cnidium and Leonurus fruits were all
present as contaminants in several samples of each of the
respective herbs. Cnidium and Leonurus especially have been
found to contaminate each-other repeatedly. The three last-
mentioned taxa are all ruderals, occurring as weeds, in ﬁeld
margins and on roadsides and therefore are likely to be accidental
contaminants. Other weedy species occurring commonly as
contaminants are Echinochloa sp. awns and caryopses (in at least
11 samples of six different herbs, especially Kochiae Fructus), and
Amaranthaceae seeds (probably Chenopodium spp.).
The higher quality (i.e. use of the correct species and absence of
contamination) of cultivated samples is not surprising, given the
greater degree of control over plant and habitat (e.g. through
weeding) during production and harvesting. It may also reﬂect the
increasingly widespread implementation of Good Agricultural
Practice (GAP) in China.
Chinese materia medica reach UK sources through a complex
chain of suppliers, and it is difﬁcult to point to the exact point that a
problem affecting quality is introduced. Our data suggest thatsome errors occur at the end point. The difference in quality
between drugs available from wholesale suppliers, with 87% of
samples supplied as the correct species and without contamina-
tion, compared to 79% from retail dispensaries, suggests that some
errors are introduced in handling within shops. Cases that are not
otherwise explicable, and probably thus represent simple matters
of mislabelling or careless handling, were Ligustrum lucidum
supplied in place of Vitex trifolia for Viticis Fructus (Man Jing Zi),
from a dispensary, and two samples of Psoraleae Fructus (Bu Gu
Zhi) obtained from a trader, one correct and containing Cullen
corylifolium seeds; the other incorrect but the identity of which has
not been possible to establish.
Confusion about similar Chinese names could have occurred in
the UK or at an earlier point in the supply chain. Two examples of
substitution were possibly due to this: replacement of He Shi
(Carpesii Fructus) by Nan He Shi (Carotae Fructus), and replace-
ment of one sample of Viticis Fructus (Man Jing Zi) by Huang Jing Zi
(Vitex negundo).
Three cases of deliberate adulteration were found; these most
likely occurred close to the point of origin, probably while the
crude drugs were being processed. These cases are an unidentiﬁed
seed instead of Bu Gu Zhi (Psoraleae Fructus) referred to above; the
stones mixed in with seeds of Sha Yuan Zi (Astragali Complanati
Semen), and the dyeing red of fruits of Nan Wu Wei Zi (Schisandrae
Sphenantherae Fructus) in three samples.
4.4. Suggested solutions
The presence of many individuals in the supply chain means
that the question of whose responsibility it is to ensure safe,
high-quality herbs is complex. Although some quality issues are
best resolved at the point of production in China or of sale in
the UK, most will beneﬁt from increased East-West dialogue
which can help to initiate, accelerate and shape outcomes as
well as promote take-up of good practice protocols. Two such
protocols, GAP for cultivated and FairWild for wild-sourced
plants, are discussed here; the WHO (2003) Guidelines on Good
Agricultural and Collection Practices (GACP) for medicinal plants
are also relevant.
Chinese Good Agricultural Practice (GAP) certiﬁcation for TCM
herbs provides documented assurance of identity, purity and
standard quality, and also indicates traceability and compliance
with heavy metal limits set by the Chinese Pharmacopoeia. By
guaranteeing cultivated origin, such certiﬁcation also ensures
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harvesting. The three downsides of GAP-certiﬁed herbs are that
their prices are higher, coverage is conﬁned to only 58 TCM herbal
drugs, and current supply falls far short of demand (Zhang et al.,
2010; Guo et al., 2014). A full list of producers of GAP-certiﬁed TCM
drugs is available from the China Food and Drug Administration
website (CFDA, 2016); as GAP certiﬁcation is issued to named
producers for named species for a limited 5-year period, this site
needs to be checked regularly for updates. A scaled-up GAP
production system would help address some of the quality issues
presented in the UK study described here.
For TCM drugs yet to be covered by GAP (i.e. by far the bulk in
international trade) the greatest variability in quality inevitably
occurs among wild-harvested species; this is due not only to the
natural variability of wild species, but also to the increased
likelihood of contamination with easily-confused species at the
point of harvest. Trying to avoid the use of wild-sourced herbs,
however, is difﬁcult since 70–80% of CMM species in world trade
continue to be wild sourced (Zhang et al., 2010). Fortunately,
recent international medicinal plant initiatives designed primar-
ily as tools for sustainable wild-harvesting and good collection
practices also include species identiﬁcation and traceability
procedures that can help address herbal quality issues (WHO,
2003; FairWild Foundation, 2010). For example, the FairWild
Standard aims ‘to identify and facilitate socially responsible
business practices for sustainable wild plant collection’ and has
recently been ﬁeld-trialled on a selection of TCM drugs in 3
Chinese provinces as part of a recent EU-China funded project, led
by TRAFFIC International (Timoshyna et al., 2015). This project
reﬂects changing attitudes within China about the sustainable
sourcing of TCM raw materials and is a promising model that
could be expanded to other CMM. As such it deserves close
evaluation by Western suppliers.
A growing understanding of medicinal plant value chains,
aimed at resolving socio-ecological impacts of complex and poorly
managed TCM supply routes, also provides many opportunities for
East-West dialogue that may help to hasten quality improvement
of CMM in world trade (Booker et al., 2012).
Further research is also required to identify the full range of
CMM sold in the UK, and in other areas outside China, so as to
identify which have the greatest quality problems. The results of
this work will then enable efforts to be most effectively directed.
Such work could not only seek to improve quality at the point of
production, but also promote more responsible attitudes and good
practice protocols in the supply of TCM herbs and even consider
whether some commonly used, closely related substitutes are in
fact suitable candidates for recognition as ofﬁcial substitutes.
Methodical data collection, as demonstrated in this paper but
covering all materia medica and a larger number of sources, will
generate valuable data for other purposes too. The popularity of
wild-harvested plants, and instances of large-scale substitution of
these, will indicate where conservation efforts should be directed
to wild plant populations. Differences between European and
Chinese prescribing practice are also likely to be found (Wil-
liamson et al., 2013), and these will be of interest to historians and
anthropologists of medicine interested in the transformation of
TCM in overseas contexts. Such market surveys are most effectively
undertaken on the basis of collaboration between researchers,
traders and the professional TCM practitioner bodies, of the kind
demonstrated in this paper as well as by the pioneering work of the
now well-established Approved Suppliers Scheme initiated and
managed by the RCHM.
The occasional use by suppliers of species-speciﬁc preﬁxes for
certain drugs (e.g. those for Wu Wei Zi – Schisandra) suggest there
is supplier conﬁdence in precisely which species is being traded;
this study however has revealed that such apparent precision is notreliable and authentication is required to be certain of the species’
identity.
5. Conclusions
According to readers’ perspectives, the headline results of this
survey can be presented either as encouraging (91% of samples
were of the correct species) or discouraging (18% of samples were
of incorrect species or had major or minor levels of contamination).
Of these incorrect species and contaminants none were considered
to pose direct health problems (i.e. none were considered to be
toxic). Most signiﬁcant, however, is that the above quality issues
were found in some of the most popular herbs (i.e. those that were
sold by the greatest number of sources), including three of the six
EHTPA-listed herbs in this study, which had, respectively, 8, 25 and
33% of samples either incorrect or contaminated.
The clinical impact of including herbs with such quality issues
in TCM prescriptions is not known. At the very least the efﬁcacy
(and possibly safety) of such a prescription will be compromised
owing to an imbalance in the ratio and assemblage (and hence
pharmacological proﬁle) of the prescription’s ingredients but it is
outside the scope of this study and its authors’ expertise to
comment on possible clinical implications. The ﬁndings of a recent
and large-scale questionnaire survey of TCM practitioners in China
and the EU state that ‘The use of CMM appears largely safe in both
areas [EU and China]’ (Williamson et al., 2013). Although physical
CMM samples were not examined in the latter study, the overall
ﬁndings of the present UK-based paper support this view.
Equivalent market studies covering more CMM over a wider
geographical area would provide further corroboration. In the
meantime, greater vigilance is needed to improve the quality of
CMM on the UK market speciﬁcally.
While resolving quality issues depends in part on the action of
suppliers and dispensers, their full resolution will depend on
collaboration with producers and regulators in and outside China
to ensure consistent standards of production (Fan et al., 2012).
Market surveys with a focus on authentication will have an
important role to play in detecting problem herbs and enabling
efforts at improvement to be focused.
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